The effects of sirolimus on wound healing in dermatologic surgery

Jerry D. Brewer, Clark C. Otley, Leslie J. Christenson, P. Kim Phillips, Randall K. Roenigk, Amy L. Weaver

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


BACKGROUND: Sirolimus, a TOR (target of rapamycin)-binding immunosuppressant, has been associated with wound healing complications; however, its effects have not been documented in dermatologic surgery. OBJECTIVE: The objective was to determine the effect of sirolimus on wound healing in dermatologic surgery. METHODS AND MATERIALS: Databases at Mayo Clinic were queried for organ transplant recipients undergoing dermatologic surgery. Medical records were reviewed retrospectively, and telephone interviews were conducted. Patients receiving sirolimus were compared with patients not receiving sirolimus. RESULTS: Postoperative infections occurred in 19.2% of the sirolimus group (n=26) and 5.4% of the controls (n=37; p=.11; odds ratio [OR], 4.2; 95% confidence interval [CI], 0.7-23.4). The incidence of wound dehiscence was greater in the sirolimus group (7.7% vs. 0%; p=.17; OR, 7.7; 95% CI, 0.4-166.3). CONCLUSION: No significantly increased risk of wound complications was found in organ transplant recipients receiving sirolimus while undergoing dermatologic surgery. However, this study was retrospective and had a small sample size. A larger study is necessary for corroboration.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalDermatologic Surgery
Issue number2
StatePublished - Feb 1 2008

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'The effects of sirolimus on wound healing in dermatologic surgery'. Together they form a unique fingerprint.

Cite this